Legend Biotech initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Legend Biotech with a Buy rating and $66 price target. Legend is a biotech company focused on development of cell therapies for the treatment of hematologic and solid tumors, the analyst tells investors in a research note. The firm says Carvykti’s "impressive" clinical data across multiple lines of myeloma therapy could position it as standard-of-care.